Literature DB >> 24958960

Sofosbuvir.

Dennis J Cada1, Jasen Cong2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The May 2014 monograph topics are droxidopa, elosulfase alfa, vorapaxar, ramucirumab, and pimavanserin. The DUE/MUE is on droxidopa.

Entities:  

Year:  2014        PMID： 24958960      PMCID： PMC4062722          DOI： 10.1310/hpj4905-466

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  19 in total

Review 1.  Treatment of chronic hepatitis C--are interferons really necessary?

Authors:  Peter Ferenci
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

2.  Sofosbuvir: the final nail in the coffin for hepatitis C?

Authors:  Michael P Manns; Markus Cornberg
Journal:  Lancet Infect Dis       Date:  2013-03-15       Impact factor: 25.071

3.  Hepatitis C in the United States.

Authors:  Scott D Holmberg; Philip R Spradling; Anne C Moorman; Maxine M Denniston
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

4.  Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.

Authors:  Kris V Kowdley; Eric Lawitz; Israel Crespo; Tarek Hassanein; Mitchell N Davis; Michael DeMicco; David E Bernstein; Nezam Afdhal; John M Vierling; Stuart C Gordon; Jane K Anderson; Robert H Hyland; Hadas Dvory-Sobol; Di An; Robert G Hindes; Efsevia Albanis; William T Symonds; M Michelle Berrey; David R Nelson; Ira M Jacobson
Journal:  Lancet       Date:  2013-03-15       Impact factor: 79.321

Review 5.  Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Authors:  Mitchell L Shiffman; Yves Benhamou
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

6.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

7.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors:  Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

8.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Authors:  Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno
Journal:  Lancet       Date:  2013-11-05       Impact factor: 79.321

9.  An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases.

Authors:  Marc G Ghany; David R Nelson; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2011-09-26       Impact factor: 17.425

10.  Exploratory study of oral combination antiviral therapy for hepatitis C.

Authors:  Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245
View more
  3 in total

1.  The FDA-approved drug sofosbuvir inhibits Zika virus infection.

Authors:  Kristen M Bullard-Feibelman; Jennifer Govero; Zhe Zhu; Vanessa Salazar; Milena Veselinovic; Michael S Diamond; Brian J Geiss
Journal:  Antiviral Res       Date:  2016-11-27       Impact factor: 5.970

2.  Investigation of the effect of verapamil on the regional absorption of sofosbuvir from rabbit intestine in situ.

Authors:  Nada M Mohsen; Esmat E Zein El-Din; Mohamed A Osman; Shimaa M Ashmawy
Journal:  Daru       Date:  2022-01-13       Impact factor: 4.088

3.  Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19.

Authors:  Frauke Assmus; Jean-Sélim Driouich; Rana Abdelnabi; Laura Vangeel; Franck Touret; Ayorinde Adehin; Palang Chotsiri; Maxime Cochin; Caroline S Foo; Dirk Jochmans; Seungtaek Kim; Léa Luciani; Grégory Moureau; Soonju Park; Paul-Rémi Pétit; David Shum; Thanaporn Wattanakul; Birgit Weynand; Laurent Fraisse; Jean-Robert Ioset; Charles E Mowbray; Andrew Owen; Richard M Hoglund; Joel Tarning; Xavier de Lamballerie; Antoine Nougairède; Johan Neyts; Peter Sjö; Fanny Escudié; Ivan Scandale; Eric Chatelain
Journal:  Microorganisms       Date:  2022-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.